Bioactive Sphingolipids in response to chemotherapy: A scope on Leukemias

Anti-Cancer Agents in Medicinal Chemistry

Volumn 11, Issue 4, 2011, Pages 385-397

  Ekiz, Huseyin Atakan ^a   Baran, Yusuf ^b  

^a UNIVERSITY OF UTAH SCHOOL OF MEDICINE   (United States)

^b IZMIR INSTITUTE OF TECHNOLOGY   (Turkey)

Author keywords

Ceramide; Ceramide 1 phosphate; Chemotherapeutic response; Dihydroceramide; Glucosylceramide; Leukemia; Sphingosine; Sphingosine 1 phosphate

Indexed keywords

1 O (ALPHA GALACTOPYRANOSYL) 2 HEXACOSANOYLAMINO 1,3,4 OCTADECANETRIOL; ALEMTUZUMAB; ALPHA GALACTOSYLCERAMIDE; ANTINEOPLASTIC AGENT; CERAMIDE; CERAMIDE 1 PHOSPHATE; CURCUMIN; DACINOSTAT; DIHYDROCERAMIDE; FAS ANTIGEN; FLUDARABINE; GLUCOSYLCERAMIDE; GLYCOPROTEIN P; METHANANDAMIDE; MONOCLONAL ANTIBODY; MULTIDRUG RESISTANCE PROTEIN 1; NITROPRUSSIDE SODIUM; PHOSPHOPROTEIN PHOSPHATASE 2A; SIALIDASE; SORAFENIB; SPHINGANINE; SPHINGOLIPID; SPHINGOSINE; SPHINGOSINE 1 PHOSPHATE; UNCLASSIFIED DRUG; VORINOSTAT;

ACUTE GRANULOCYTIC LEUKEMIA; ACUTE LYMPHOBLASTIC LEUKEMIA; APOPTOSIS; CANCER CELL; CANCER CHEMOTHERAPY; CELL DEATH; CELL GROWTH; CELL SURVIVAL; CELL VIABILITY; CHRONIC LYMPHATIC LEUKEMIA; CHRONIC MYELOID LEUKEMIA; CYTOTOXICITY; DRUG EFFICACY; DRUG RESISTANCE; ENZYME ACTIVITY; GROWTH RETARDATION; LEUKEMIA; LEUKEMIA CELL; LIPID METABOLISM; MELANOMA CELL; MYELOMA; PROTEIN DEPHOSPHORYLATION; PROTEIN FUNCTION; REVIEW; SOLID TUMOR; TREATMENT RESPONSE; UPREGULATION;

EID: 79958126314     PISSN: 18715206     EISSN: 18755992     Source Type: Journal    
DOI: 10.2174/187152011795677571     Document Type: Review

References (226)

1. Obeid, L.M.; Linardic, C.M.; Karolak, L.A.; Hannun, Y.A. Programmed cell death induced by ceramide. Science, 1993, 259(5102), 1769-1771.
2. Wang, G.; Silva, J.; Krishnamurthy, K.; Tran, E.; Condie, B.G.; Bieberich, E. Direct binding to ceramide activates protein kinase Czeta before the formation of a pro-apoptotic complex with PAR-4 in differentiating stem cells. J. Biol. Chem., 2005, 280(28), 26415-26424.
3. Zhou, H.; Summers, S.A.; Birnbaum, M.J.; Pittman, R.N. Inhibition of Akt kinase by cell-permeable ceramide and its implications for ceramide-induced apoptosis. J. Biol. Chem., 1998, 273(26), 16568-16575.
4. Kim, M.Y.; Linardic, C.; Obeid, L.; Hannun, Y. Identification of sphingomyelin turnover as an effector mechanism for the action of tumor necrosis factor alpha and gamma-interferon. Specific role in cell differentiation. J. Biol. Chem., 1991, 266(1), 484-489.
5. Le Stunff, H.; Galve-Roperh, I.; Peterson, C.; Milstien, S.; Spiegel, S. Sphingosine-1-phosphate phosphohydrolase in regulation of sphingolipid metabolism and apoptosis. J. Cell Biol., 2002, 158(6), 1039-1049.
6. Patwardhan, G.A.; Liu, Y.Y. Sphingolipids and expression regulation of genes in cancer. Prog. Lipid Res., 2010.
7. Breslow, D.K.; Weissman, J.S. Membranes in balance: mechanisms of sphingolipid homeostasis. Mol. Cell, 2010, 40(2), 267-279.
8. Hannun, Y.A.; Obeid, L.M. Principles of bioactive lipid signalling: lessons from sphingolipids. Nat Rev Mol. Cell Biol., 2008, 9(2), 139-150.
9. Bielawski, J.; Szulc, Z.M.; Hannun, Y.A.; Bielawska, A. Simultaneous quantitative analysis of bioactive sphingolipids by high-performance liquid chromatography-tandem mass spectrometry. Methods, 2006, 39(2), 82-91.
10. Merrill, A.H.; Wang, E.; Mullins, R.E. Kinetics of long-chain (sphingoid) base biosynthesis in intact LM cells: effects of varying the extracellular concentrations of serine and fatty acid precursors of this pathway. Biochemistry, 1988, 27(1), 340-345.
11. Nagiec, M.M.; Lester, R.L.; Dickson, R.C. Sphingolipid synthesis: identification and characterization of mammalian cDNAs encoding the Lcb2 subunit of serine palmitoyltransferase. Gene, 1996, 177(1-2), 237-241.
12. Linn, S.C.; Kim, H.S.; Keane, E.M.; Andras, L.M.; Wang, E.; Merrill, A.H. Regulation of de novo sphingolipid biosynthesis and the toxic consequences of its disruption. Biochem. Soc. Trans., 2001, 29(Pt 6), 831-835.
13. Lahiri, S.; Futerman, A.H. LASS5 is a bona fide dihydroceramide synthase that selectively utilizes palmitoyl-CoA as acyl donor. J. Biol. Chem., 2005, 280(40), 33735-33738.
14. Pewzner-Jung, Y.; Ben-Dor, S.; Futerman, A.H. When do Lasses (longevity assurance genes) become CerS (ceramide synthases)?: Insights into the regulation of ceramide synthesis. J. Biol. Chem., 2006, 281(35), 25001-25005.
15. Causeret, C.; Geeraert, L.; Van der Hoeven, G.; Mannaerts, G.P.; Van Veldhoven, P.P. Further characterization of rat dihydroceramide desaturase: tissue distribution, subcellular localization, and substrate specificity. Lipids, 2000, 35(10), 1117-1125.
16. Geeraert, L.; Mannaerts, G.P.; van Veldhoven, P.P. Conversion of dihydroceramide into ceramide: involvement of a desaturase. Biochem. J., 1997, 327 (Pt 1)125-132.
17. Xu, R.; Sun, W.; Jin, J.; Obeid, L.M.; Mao, C. Role of alkaline ceramidases in the generation of sphingosine and its phosphate in erythrocytes. FASEB J., 2010, 24(7), 2507-2515.
18. Clarke, C.J.; Snook, C.F.; Tani, M.; Matmati, N.; Marchesini, N.; Hannun, Y.A. The extended family of neutral sphingomyelinases. Biochemistry, 2006, 45(38), 11247-11256.
19. Marchesini, N.; Hannun, Y.A. Acid and neutral sphingomyelinases: roles and mechanisms of regulation. Biochem. Cell Biol., 2004, 82(1), 27-44.
20. Tafesse, F.G.; Ternes, P.; Holthuis, J.C. The multigenic sphingomyelin synthase family. J. Biol. Chem., 2006, 281(40), 29421-29425.
21. Hanada, K.; Kumagai, K.; Yasuda, S.; Miura, Y.; Kawano, M.; Fukasawa, M.; Nishijima, M. Molecular machinery for non-vesicular trafficking of ceramide. Nature, 2003, 426(6968), 803-809.
22. Kitatani, K.; Idkowiak-Baldys, J.; Hannun, Y.A. The sphingolipid salvage pathway in ceramide metabolism and signaling. Cell Signal., 2008, 20(6), 1010-1018.
23. Kitatani, K.; Sheldon, K.; Rajagopalan, V.; Anelli, V.; Jenkins, R.W.; Sun, Y.; Grabowski, G.A.; Obeid, L.M.; Hannun, Y.A. Involvement of acid beta-glucosidase 1 in the salvage pathway of ceramide formation. J. Biol. Chem., 2009, 284(19), 12972-12978.
24. Ichikawa, S.; Hirabayashi, Y. Glucosylceramide synthase and glycosphingolipid synthesis. Trends Cell Biol, 1998, 8(5), 198-202.
25. Mao, Z.; Sun, W.; Xu, R.; Novgorodov, S.; Szulc, Z.M.; Bielawski, J.; Obeid, L.M.; Mao, C. Alkaline ceramidase 2 (ACER2) and its product dihydrosphingosine mediate the cytotoxicity of N-(4-hydroxyphenyl)retinamide in tumor cells. J. Biol. Chem., 2010, 285(38), 29078-29090.
26. Ohlsson, L.; Palmberg, C.; Duan, R.D.; Olsson, M.; Bergman, T.; Nilsson, A. Purification and characterization of human intestinal neutral ceramidase. Biochimie, 2007, 89(8), 950-960.
27. Bernardo, K.; Hurwitz, R.; Zenk, T.; Desnick, R.J.; Ferlinz, K.; Schuchman, E.H.; Sandhoff, K. Purification, characterization, and biosynthesis of human acid ceramidase. J. Biol. Chem., 1995, 270(19), 11098-11102.
28. Hait, N.C.; Oskeritzian, C.A.; Paugh, S.W.; Milstien, S.; Spiegel, S. Sphingosine kinases, sphingosine 1-phosphate, apoptosis and diseases. Biochim. Biophys. Acta, 2006, 1758(12), 2016-2026.
29. Bandhuvula, P.; Saba, J.D. Sphingosine-1-phosphate lyase in immunity and cancer: silencing the siren. Trends Mol. Med., 2007, 13(5), 210-217.
30. Halter, D.; Neumann, S.; van Dijk, S.M.; Wolthoorn, J.; de Maziere, A.M.; Vieira, O.V.; Mattjus, P.; Klumperman, J.; van Meer, G.; Sprong, H. Pre-and post-Golgi translocation of glucosylceramide in glycosphingolipid synthesis. J. Cell Biol., 2007, 179(1), 101-115.
31. D'Angelo, G.; Polishchuk, E.; di Tullio, G.; Santoro, M.; di Campli, A.; Godi, A.; West, G.; Bielawski, J.; Chuang, C.C.; van der Spoel, A.C.; Platt, F.M.; Hannun, Y.A.; Polishchuk, R.; Mattjus, P.; de Matteis, M.A. Glycosphingolipid synthesis requires FAPP2 transfer of glucosylceramide. Nature, 2007, 449(7158), 62-67.
32. Eckford, P.D.; Sharom, F.J. P-glycoprotein (ABCB1) interacts directly with lipid-based anti-cancer drugs and platelet-activating factors. Biochem. Cell Biol., 2006, 84(6), 1022-1033.
33. Carstea, E.D.; Murray, G.J.; O'Neill, R.R. Molecular and functional characterization of the murine glucocerebrosidase gene. Biochem. Biophys. Res. Commun., 1992, 184(3), 1477-1483.
34. Wijesinghe, D.S.; Massiello, A.; Subramanian, P.; Szulc, Z.; Bielawska, A.; Chalfant, C.E. Substrate specificity of human ceramide kinase. J. Lipid Res., 2005, 46(12), 2706-2716.
35. Ekiz, H.A.; Baran, Y. Therapeutic applications of bioactive sphingolipids in hematological malignancies. Int. J. Cancer, 2010, 127(7), 1497-1506.
36. Duan, R.D.; Nilsson, A. Metabolism of sphingolipids in the gut and its relation to inflammation and cancer development. Prog. Lipid Res., 2009, 48(1), 62-72.
37. Zeidan, Y.H.; Jenkins, R.W.; Korman, J.B.; Liu, X.; Obeid, L.M.; Norris, J.S.; Hannun, Y.A. Molecular targeting of acid ceramidase: implications to cancer therapy. Curr. Drug Targets, 2008, 9(8), 653-661.
38. Mora, R.; Dokic, I.; Kees, T.; Huber, C.M.; Keitel, D.; Geibig, R.; Brugge, B.; Zentgraf, H.; Brady, N.R.; Regnier-Vigouroux, A. Sphingolipid rheostat alterations related to transformation can be exploited for specific induction of lysosomal cell death in murine and human glioma. Glia, 2010, 58(11), 1364-1383.
39. Lavieu, G.; Scarlatti, F.; Sala, G.; Carpentier, S.; Levade, T.; Ghidoni, R.; Botti, J.; Codogno, P. Sphingolipids in macro-autophagy. Methods Mol. Biol., 2008, 445,159-173.
40. Baumruker, T.; Prieschl, E.E. Sphingolipids and the regulation of the immune response. Semin. Immunol., 2002, 14(1), 57-63.
41. Mandala, S.M.; Thornton, R.; Tu, Z.; Kurtz, M.B.; Nickels, J.; Broach, J.; Menzeleev, R.; Spiegel, S. Sphingoid base 1-phosphate phosphatase: a key regulator of sphingolipid metabolism and stress response. Proc. Natl. Acad. Sci. USA, 1998, 95(1), 150-155.
42. Sauane, M.; Su, Z.Z.; Dash, R.; Liu, X.; Norris, J.S.; Sarkar, D.; Lee, S.G.; Allegood, J.C.; Dent, P.; Spiegel, S.; Fisher, P.B. Ceramide plays a prominent role in MDA-7/IL-24-induced cancer-specific apoptosis. J Cell Physiol, 2010, 222(3), 546-555.
43. Kim, S.W.; Kim, H.J.; Chun, Y.J.; Kim, M.Y. Ceramide produces apoptosis through induction of p27(kip1) by protein phosphatase 2A-dependent Akt dephosphorylation in PC-3 prostate cancer cells. J. Toxicol. Environ. Health A, 2010, 73(21-22), 1465-1476.
44. Oh, J.E.; So, K.S.; Lim, S.J.; Kim, M.Y. Induction of apoptotic cell death by a ceramide analog in PC-3 prostate cancer cells. Arch Pharm Res, 2006, 29(12), 1140-1146.
45. Siskind, L.J.; Feinstein, L.; Yu, T.; Davis, J.S.; Jones, D.; Choi, J.; Zuckerman, J.E.; Tan, W.; Hill, R.B.; Hardwick, J.M.; Colombini, M. Anti-apoptotic Bcl-2 Family Proteins Disassemble Ceramide Channels. J. Biol. Chem., 2008, 283(11), 6622-6630.
46. Hou, Q.; Jin, J.; Zhou, H.; Novgorodov, S.A.; Bielawska, A.; Szulc, Z.M.; Hannun, Y.A.; Obeid, L.M.; Hsu, Y.T. Mitochondrially targeted ceramides preferentially promote autophagy, retard cell growth, and induce apoptosis. J. Lipid Res., 2011, 52(2), 278-88.
47. Bandyopadhyay, S.; Zhan, R.; Wang, Y.; Pai, S.K.; Hirota, S.; Hosobe, S.; Takano, Y.; Saito, K.; Furuta, E.; Iiizumi, M.; Mohinta, S.; Watabe, M.; Chalfant, C.; Watabe, K. Mechanism of apoptosis induced by the inhibition of fatty acid synthase in breast cancer cells. Cancer Res., 2006, 66(11), 5934-5940.
48. Richter, C.; Ghafourifar, P. Ceramide induces cytochrome c release from isolated mitochondria. Biochem. Soc. Symp., 1999, 6627-31.
49. de Castroe Paula, L.A.; Hansen, P.J. Ceramide inhibits development and cytokinesis and induces apoptosis in preimplantation bovine embryos. Mol Reprod Dev, 2008, 75(6), 1063-1070.
50. Huber, L.C.; Jungel, A.; Distler, J.H.; Moritz, F.; Gay, R.E.; Michel, B.A.; Pisetsky, D.S.; Gay, S.; Distler, O. The role of membrane lipids in the induction of macrophage apoptosis by microparticles. Apoptosis, 2007, 12(2), 363-374.
51. Devillard, R.; Galvani, S.; Thiers, J.C.; Guenet, J.L.; Hannun, Y.; Bielawski, J.; Negre-Salvayre, A.; Salvayre, R.; Auge, N. Stress-induced sphingolipid signaling: role of type-2 neutral sphingomyelinase in murine cell apoptosis and proliferation. PLoS One, 2010, 5(3), e9826.
52. Ichi, I.; Kamikawa, C.; Nakagawa, T.; Kobayashi, K.; Kataoka, R.; Nagata, E.; Kitamura, Y.; Nakazaki, C.; Matsura, T.; Kojo, S. Neutral sphingomyelinase-induced ceramide accumulation by oxidative stress during carbon tetrachloride intoxication. Toxicology, 2009, 261(1-2), 33-40.
53. Deng, X.; Yin, X.; Allan, R.; Lu, D.D.; Maurer, C.W.; Haimovitz-Friedman, A.; Fuks, Z.; Shaham, S.; Kolesnick, R. Ceramide biogenesis is required for radiation-induced apoptosis in the germ line of C. Elegans. Science, 2008, 322(5898), 110-115.
54. Verheij, M.; van Blitterswijk, W.J.; Bartelink, H. Radiation-induced apoptosis--the ceramide-SAPK signaling pathway and clinical aspects. Acta Oncol., 1998, 37(6), 575-581.
55. Yabu, T.; Imamura, S.; Yamashita, M.; Okazaki, T. Identification of Mg2+ -dependent neutral sphingomyelinase 1 as a mediator of heat stress-induced ceramide generation and apoptosis. J. Biol. Chem., 2008, 283(44), 29971-29982.
56. Lei, X.; Zhang, S.; Bohrer, A.; Ramanadham, S. Calcium-independent phospholipase A2 (iPLA2 beta)-mediated ceramide generation plays a key role in the cross-talk between the endoplasmic reticulum (ER) and mitochondria during ER stress-induced insulin-secreting cell apoptosis. J. Biol. Chem., 2008, 283(50), 34819-34832.
57. Lei, X.; Zhang, S.; Bohrer, A.; Bao, S.; Song, H.; Ramanadham, S. The group VIA calcium-independent phospholipase A2 participates in ER stress-induced INS-1 insulinoma cell apoptosis by promoting ceramide generation via hydrolysis of sphingomyelins by neutral sphingomyelinase. Biochemistry, 2007, 46(35), 10170-10185.
58. Takahashi, E.; Inanami, O.; Asanuma, T.; Kuwabara, M. Effects of ceramide inhibition on radiation-induced apoptosis in human leukemia MOLT-4 cells. J. Radiat. Res. (Tokyo), 2006, 47(1), 19-25.
59. Senkal, C.E.; Ponnusamy, S.; Bielawski, J.; Hannun, Y.A.; Ogretmen, B. Antiapoptotic roles of ceramide-synthase-6-generated C16-ceramide via selective regulation of the ATF6/CHOP arm of ER-stress-response pathways. FASEB J., 2010, 24(1), 296-308.
60. Mancinetti, A.; Di Bartolomeo, S.; Spinedi, A. Long-chain ceramide produced in response to N-hexanoylsphingosine does not induce apoptosis in CHP-100 cells. Lipids, 2009, 44(11), 1039-1046.
61. Novgorodov, S.A.; Gudz, T.I.; Obeid, L.M. Long-chain ceramide is a potent inhibitor of the mitochondrial permeability transition pore. J. Biol. Chem., 2008, 283(36), 24707-24717.
62. Gomez-Munoz, A.; Kong, J.Y.; Salh, B.; Steinbrecher, U.P. Ceramide-1-phosphate blocks apoptosis through inhibition of acid sphingomyelinase in macrophages. J. Lipid Res., 2004, 45(1), 99-105.
63. Gomez-Munoz, A.; Duffy, P.A.; Martin, A.; O'Brien, L.; Byun, H.S.; Bittman, R.; Brindley, D.N. Short-chain ceramide-1-phosphates are novel stimulators of DNA synthesis and cell division: antagonism by cell-permeable ceramides. Mol. Pharmacol., 1995, 47(5), 833-839.
64. Gangoiti, P.; Granado, M.H.; Arana, L.; Ouro, A.; Gomez-Munoz, A. Activation of protein kinase C-alpha is essential for stimulation of cell proliferation by ceramide 1-phosphate. FEBS Lett., 2010, 584(3), 517-524.
65. Granado, M.H.; Gangoiti, P.; Ouro, A.; Arana, L.; Gomez-Munoz, A. Ceramide 1-phosphate inhibits serine palmitoyltransferase and blocks apoptosis in alveolar macrophages. Biochim. Biophys. Acta, 2009, 1791(4), 263-272.
66. Gangoiti, P.; Granado, M.H.; Arana, L.; Ouro, A.; Gomez-Munoz, A. Involvement of nitric oxide in the promotion of cell survival by ceramide 1-phosphate. FEBS Lett., 2008, 582(15), 2263-2269.
67. Gangoiti, P.; Granado, M.H.; Wang, S.W.; Kong, J.Y.; Steinbrecher, U.P.; Gomez-Munoz, A. Ceramide 1-phosphate stimulates macrophage proliferation through activation of the PI3-kinase/PKB, JNK and ERK1/2 pathways. Cell Signal., 2008, 20(4), 726-736.
68. Goldsmith, M.; Avni, D.; Levy-Rimler, G.; Mashiach, R.; Ernst, O.; Levi, M.; Webb, B.; Meijler, M.M.; Gray, N.S.; Rosen, H.; Zor, T. A ceramide-1-phosphate analogue, PCERA-1, simultaneously suppresses tumour necrosis factor-alpha and induces interleukin-10 production in activated macrophages. Immunology, 2009, 127(1), 103-115.
69. Jozefowski, S.; Czerkies, M.; Lukasik, A.; Bielawska, A.; Bielawski, J.; Kwiatkowska, K.; Sobota, A. Ceramide and ceramide 1-phosphate are negative regulators of TNF-alpha production induced by lipopolysaccharide. J. Immunol., 2010, 185(11), 6960-6973.
70. Gomez-Munoz, A.; Gangoiti, P.; Granado, M.H.; Arana, L.; Ouro, A. Ceramide-1-phosphate in cell survival and inflammatory signaling. Adv. Exp. Med. Biol., 2010, 688, 118-130.
71. Saxena, S.; Banerjee, M.; Shirumalla, R.K.; Ray, A. Ceramide kinase: a potential anti-inflammatory target? Curr. Opin. Investig. Drugs, 2008, 9(5), 455-462.
72. Hinkovska-Galcheva, V.; Shayman, J.A. Ceramide-1-phosphate in phagocytosis and calcium homeostasis. Adv. Exp. Med. Biol., 2010, 688, 131-140.
73. Mitsutake, S.; Kumada, H.; Soga, M.; Hurue, Y.; Asanuma, F.; Nagira, M.; Deguchi, M.; Date, T.; Yokose, U.; Inagaki, Y.; Sugiura, M.; Kohama, T.; Igarashi, Y. Ceramide kinase is not essential but might act as an Ca2+-sensor for mast cell activation. Prostaglandins Other Lipid Mediat, 2010, 93(3-4), 109-112.
74. Hinkovska-Galcheva, V.; VanWay, S.M.; Shanley, T.P.; Kunkel, R.G. The role of sphingosine-1-phosphate and ceramide-1-phosphate in calcium homeostasis. Curr. Opin. Investig. Drugs, 2008, 9(11), 1192-1205.
75. Barth, B.M.; Gustafson, S.J.; Young, M.M.; Shanmugavelandy, S.S.; Kaiser, J.M.; Cabot, M.C.; Kester, M.; Kuhn, T.B. Inhibition of NADPH oxidase by glucosylceramide confers chemoresistance. Cancer Biol. Ther., 2010, 10, (11).
76. Li, R.; Manela, J.; Kong, Y.; Ladisch, S. Cellular gangliosides promote growth factor-induced proliferation of fibroblasts. J. Biol. Chem., 2000, 275(44), 34213-34223.
77. Lucci, A.; Cho, W.I.; Han, T.Y.; Giuliano, A.E.; Morton, D.L.; Cabot, M.C. Glucosylceramide: a marker for multiple-drug resistant cancers. Anticancer Res., 1998, 18(1B), 475-480.
78. Chapman, J.V.; Gouaze-Andersson, V.; Cabot, M.C. Expression of P-glycoprotein in HeLa cells confers resistance to ceramide cytotoxicity. Int. J. Oncol., 2010, 37(6), 1591-1597.
79. Liu, Y.Y.; Gupta, V.; Patwardhan, G.A.; Bhinge, K.; Zhao, Y.; Bao, J.; Mehendale, H.; Cabot, M.C.; Li, Y.T.; Jazwinski, S.M. Glucosylceramide synthase upregulates MDR1 expression in the regulation of cancer drug resistance through cSrc and beta-catenin signaling. Mol. Cancer, 2010, 91, 45.
80. Liu, Y.; Xie, K.M.; Yang, G.Q.; Bai, X.M.; Shi, Y.P.; Mu, H.J.; Qiao, W.Z.; Zhang, B.; Xie, P. GCS induces multidrug resistance by regulating apoptosis-related genes in K562/AO2 cell line. Cancer Chemother. Pharmacol., 2010, 66(3), 433-439.
81. Sun, C.C.; Zhang, Z.; Zhang, S.Y.; Li, J.; Li, Z.L.; Kong, C.Z. Up-regulation of glucosylceramide synthase in urinary bladder neoplasms. Urol. Oncol., 2010.
82. Ruckhaberle, E.; Karn, T.; Hanker, L.; Gatje, R.; Metzler, D.; Holtrich, U.; Kaufmann, M.; Rody, A. Prognostic relevance of glucosylceramide synthase (GCS) expression in breast cancer. J. Cancer Res. Clin. Oncol., 2009, 135(1), 81-90.
83. Bodamer, O.A.; Hung, C. Laboratory and genetic evaluation of Gaucher disease. Wien Med Wochenschr, 2010.
84. Natoli, T.A.; Smith, L.A.; Rogers, K.A.; Wang, B.; Komarnitsky, S.; Budman, Y.; Belenky, A.; Bukanov, N.O.; Dackowski, W.R.; Husson, H.; Russo, R.J.; Shayman, J.A.; Ledbetter, S.R.; Leonard, J.P.; Ibraghimov-Beskrovnaya, O. Inhibition of glucosylceramide accumulation results in effective blockade of polycystic kidney disease in mouse models. Nat. Med., 2010, 16(7), 788-792.
85. Karman, J.; Tedstone, J.L.; Gumlaw, N.K.; Zhu, Y.; Yew, N.; Siegel, C.; Guo, S.; Siwkowski, A.; Ruzek, M.; Jiang, C.; Cheng, S.H. Reducing glycosphingolipid biosynthesis in airway cells partially ameliorates disease manifestations in a mouse model of asthma. Int. Immunol., 2010, 22(7), 593-603.
86. Santha, P.; Oszlacs, O.; Dux, M.; Dobos, I.; Jancso, G. Inhibition of glucosylceramide synthase reversibly decreases the capsaicin-induced activation and TRPV1 expression of cultured dorsal root ganglion neurons. Pain, 2010, 150(1), 103-112.
87. Stefanic, S.; Spycher, C.; Morf, L.; Fabrias, G.; Casas, J.; Schraner, E.; Wild, P.; Hehl, A.B.; Sonda, S. Glucosylceramide synthesis inhibition affects cell cycle progression, membrane trafficking, and stage differentiation in Giardia lamblia. J. Lipid Res., 2010, 51(9), 2527-2545.
88. Ben Ya'acov, A.; Lalazar, G.; Livovsky, D.M.; Kanovich, D.; Axelrod, E.; Preston, S.; Schwarzmann, G.; Ilan, Y. Decreased STAT-1 phosphorylation by a thio analogue of beta-D-glucosylceramide is associated with altered NKT lymphocyte polarization. Mol. Immunol., 2009, 47(2-3), 526-533.
89. Ahn, E.H.; Schroeder, J.J. Sphingoid bases and ceramide induce apoptosis in HT-29 and HCT-116 human colon cancer cells. Exp. Biol. Med. (Maywood), 2002, 227(5), 345-353.
90. Bielawska, A.; Crane, H.M.; Liotta, D.; Obeid, L.M.; Hannun, Y.A. Selectivity of ceramide-mediated biology. Lack of activity of erythro-dihydroceramide. J. Biol. Chem., 1993, 268(35), 26226-26232.
91. Shikata, K.; Niiro, H.; Azuma, H.; Ogino, K.; Tachibana, T. Apoptotic activities of C2-ceramide and C2-dihydroceramide homologues against HL-60 cells. Bioorg. Med. Chem., 2003, 11(13), 2723-2728.
92. Shikata, K.; Niiro, H.; Azuma, H.; Tachibana, T.; Ogino, K. Synthesis of non-natural C2-homo-ceramide and its apoptotic activity against HL-60 cells. Bioorg. Med. Chem. Lett., 2003, 13(4), 613-616.
93. Illuzzi, G.; Bernacchioni, C.; Aureli, M.; Prioni, S.; Frera, G.; Donati, C.; Valsecchi, M.; Chigorno, V.; Bruni, P.; Sonnino, S.; Prinetti, A. Sphingosine kinase mediates resistance to the synthetic retinoid N-(4-hydroxyphenyl)retinamide in human ovarian cancer cells. J. Biol. Chem., 2010, 285(24), 18594-18602.
94. Munoz-Olaya, J.M.; Matabosch, X.; Bedia, C.; Egido-Gabas, M.; Casas, J.; Llebaria, A.; Delgado, A.; Fabrias, G. Synthesis and biological activity of a novel inhibitor of dihydroceramide desaturase. Chem. Med. Chem., 2008, 3(6), 946-953.
95. Stiban, J.; Fistere, D.; Colombini, M. Dihydroceramide hinders ceramide channel formation: Implications on apoptosis. Apoptosis, 2006, 11(5), 773-780.
96. Schulz, A.; Mousallem, T.; Venkataramani, M.; Persaud-Sawin, D.A.; Zucker, A.; Luberto, C.; Bielawska, A.; Bielawski, J.; Holthuis, J.C.; Jazwinski, S.M.; Kozhaya, L.; Dbaibo, G.S.; Boustany, R.M. The CLN9 protein, a regulator of dihydroceramide synthase. J. Biol. Chem., 2006, 281(5), 2784-2794.
97. Separovic, D.; Kelekar, A.; Nayak, A.K.; Tarca, A.L.; Hanada, K.; Pierce, J.S.; Bielawski, J. Increased ceramide accumulation correlates with downregulation of the autophagy protein ATG-7 in MCF-7 cells sensitized to photodamage. Arch. Biochem. Biophys., 2010, 494(1), 101-105.
98. Signorelli, P.; Munoz-Olaya, J.M.; Gagliostro, V.; Casas, J.; Ghidoni, R.; Fabrias, G. Dihydroceramide intracellular increase in response to resveratrol treatment mediates autophagy in gastric cancer cells. Cancer Lett., 2009, 282(2), 238-243.
99. Wang, H.; Maurer, B.J.; Liu, Y.Y.; Wang, E.; Allegood, J.C.; Kelly, S.; Symolon, H.; Liu, Y.; Merrill, A.H.; Gouaze-Andersson, V.; Yu, J.Y.; Giuliano, A.E.; Cabot, M.C. N-(4-Hydroxyphenyl)retinamide increases dihydroceramide and synergizes with dimethylsphingosine to enhance cancer cell killing. Mol. Cancer Ther., 2008, 7(9), 2967-2976.
100. Sweeney, E.A.; Sakakura, C.; Shirahama, T.; Masamune, A.; Ohta, H.; Hakomori, S.; Igarashi, Y. Sphingosine and its methylated derivative N,N-dimethylsphingosine (DMS) induce apoptosis in a variety of human cancer cell lines. Int J Cancer, 1996, 66(3), 358-366.
101. Klostergaard, J.; Auzenne, E.; Leroux, E. Characterization of cytotoxicity induced by sphingolipids in multidrug-resistant leukemia cells. Leuk. Res., 1998, 22(11), 1049-1056.
102. Jarvis, W.D.; Fornari, F.A.; Traylor, R.S.; Martin, H.A.; Kramer, L.B.; Erukulla, R.K.; Bittman, R.; Grant, S. Induction of apoptosis and potentiation of ceramide-mediated cytotoxicity by sphingoid bases in human myeloid leukemia cells. J. Biol. Chem., 1996, 271(14), 8275-8284.
103. Ohta, H.; Sweeney, E.A.; Masamune, A.; Yatomi, Y.; Hakomori, S.; Igarashi, Y. Induction of apoptosis by sphingosine in human leukemic HL-60 cells: a possible endogenous modulator of apoptotic DNA fragmentation occurring during phorbol ester-induced differentiation. Cancer Res., 1995, 55(3), 691-697.
104. Shirahama, T.; Sweeney, E.A.; Sakakura, C.; Singhal, A.K.; Nishiyama, K.; Akiyama, S.; Hakomori, S.; Igarashi, Y. In vitro and in vivo induction of apoptosis by sphingosine and N, N-dimethylsphingosine in human epidermoid carcinoma KB-3-1 and its multidrug-resistant cells. Clin. Cancer Res., 1997, 3(2), 257-264.
105. Auzenne, E.; Leroux, M.E.; Hu, M.; Pollock, R.E.; Feig, B.; Klostergaard, J. Cytotoxic effects of sphingolipids as single or multi-modality agents on human melanoma and soft tissue sarcoma in vitro. Melanoma Res., 1998, 8(3), 227-239.
106. Kanno, T.; Nishizaki, T. Sphingosine induces apoptosis in hippocampal neurons and astrocytes by activating caspase-3/-9 via a mitochondrial pathway linked to SDK/14-3-3 Protein/Bax/ Cytochrome c. J. Cell Physiol., 2010.
107. Hannun, Y.A.; Loomis, C.R.; Merrill, A.H., Jr.; Bell, R.M. Sphingosine inhibition of protein kinase C activity and of phorbol dibutyrate binding in vitro and in human platelets. J. Biol. Chem., 1986, 261(27), 12604-12609.
108. Petrusca, D.N.; Gu, Y.; Adamowicz, J.J.; Rush, N.I.; Hubbard, W.C.; Smith, P.A.; Berdyshev, E.V.; Birukov, K.G.; Lee, C.H.; Tuder, R.M.; Twigg, H.L., 3rd; Vandivier, R.W.; Petrache, I. Sphingolipid-mediated Inhibition of Apoptotic Cell Clearance by Alveolar Macrophages. J. Biol. Chem., 2010, 285(51), 40322-40332.
109. Bonnaud, S.; Niaudet, C.; Legoux, F.; Corre, I.; Delpon, G.; Saulquin, X.; Fuks, Z.; Gaugler, M.H.; Kolesnick, R.; Paris, F. Sphingosine-1-Phosphate Activates the AKT Pathway to Protect Small Intestines from Radiation-Induced Endothelial Apoptosis. Cancer Res. 2010, 70(23), 9905-9915.
110. Huwiler, A.; Kotelevets, N.; Xin, C.; Pastukhov, O.; Pfeilschifter, J.; Zangemeister-Wittke, U. Loss of sphingosine kinase-1 in carcinoma cells increases formation of reactive oxygen species and sensitivity to doxorubicin-induced DNA damage. Br J Pharmacol, 2011, 162(2), 532-543.
111. Teicher, B.A. Antiangiogenic agents and targets: A perspective. Biochem. Pharmacol., 2011, 81(1), 6-12.
112. Schwalm, S.; Pfeilschifter, J.; Huwiler, A. Sphingosine kinase 1 is critically involved in nitric oxide-mediated human endothelial cell migration and tube formation. Br. J. Pharmacol., 2010, 160(7), 1641-1651.
113. Keul, P.; Lucke, S.; von Wnuck Lipinski, K.; Bode, C.; Graler, M.; Heusch, G.; Levkau, B. Sphingosine-1-Phosphate Receptor 3 Promotes Recruitment of Monocyte/Macrophages in Inflammation and Atherosclerosis. Circ. Res., 2010.
114. Li, C.; Zheng, S.; You, H.; Liu, X.; Lin, M.; Yang, L.; Li, L. Sphingosine 1-Phosphate (S1P)/S1P Receptors Is Involved in Human Liver Fibrosis by Action on Hepatic Myofibroblasts Motility. J. Hepatol., 2010.
115. Ishii, M.; Kikuta, J.; Shimazu, Y.; Meier-Schellersheim, M.; Germain, R.N. Chemorepulsion by blood S1P regulates osteoclast precursor mobilization and bone remodeling in vivo. J. Exp. Med., 2010, 207(13), 2793-2798.
116. Liu, X.; Yue, S.; Li, C.; Yang, L.; You, H.; Li, L. Essential roles of sphingosine 1-phosphate receptor type 1 and 3 in human hepatic stellate cells motility and activation. J. Cell Physiol., 2010.
117. Lee, C.W.; Choi, J.W.; Chun, J. Neurological S1P signaling as an emerging mechanism of action of oral FTY720 (Fingolimod) in multiple sclerosis. Arch. Pharm. Res., 2010, 33(10), 1567-1574.
118. Noguchi, K.; Chun, J. Roles for lysophospholipid S1P receptors in multiple sclerosis. Crit. Rev. Biochem. Mol. Biol., 2010.
119. Hu, P.F.; Chen, Y.; Cai, P.F.; Jiang, L.F.; Wu, L.D. Sphingosine-1-phosphate: a potential therapeutic target for rheumatoid arthritis. Mol. Biol. Rep., 2010.
120. Lai, W.Q.; Wong, W.S.; Leung, B.P. Sphingosine kinase and sphingosine 1-phosphate in asthma. Biosci. Rep., 2011, 31(2), 145-150.
121. Lai, W.Q.; Irwan, A.W.; Goh, H.H.; Melendez, A.J.; McInnes, I.B.; Leung, B.P. Distinct roles of sphingosine kinase 1 and 2 in murine collagen-induced arthritis. J. Immunol., 2009, 183(3), 2097-2103.
122. Wadgaonkar, R.; Patel, V.; Grinkina, N.; Romano, C.; Liu, J.; Zhao, Y.; Sammani, S.; Garcia, J.G.; Natarajan, V. Differential regulation of sphingosine kinases 1 and 2 in lung injury. Am. J. Physiol. Lung Cell Mol. Physiol., 2009, 296(4), L603-L613.
123. Oskeritzian, C.A.; Alvarez, S.E.; Hait, N.C.; Price, M.M.; Milstien, S.; Spiegel, S. Distinct roles of sphingosine kinases 1 and 2 in human mast-cell functions. Blood, 2008, 111(8), 4193-4200.
124. Maceyka, M.; Sankala, H.; Hait, N.C.; Le Stunff, H.; Liu, H.; Toman, R.; Collier, C.; Zhang, M.; Satin, L.S.; Merrill, A.H.; Milstien, S.; Spiegel, S. SphK1 and SphK2, sphingosine kinase isoenzymes with opposing functions in sphingolipid metabolism. J. Biol. Chem., 2005, 280(44), 37118-37129.
125. Hilchie, A.L.; Furlong, S.J.; Sutton, K.; Richardson, A.; Robichaud, M.R.; Giacomantonio, C.A.; Ridgway, N.D.; Hoskin, D.W. Curcumin-induced apoptosis in PC3 prostate carcinoma cells is caspase-independent and involves cellular ceramide accumulation and damage to mitochondria. Nutr. Cancer, 2010, 62(3), 379-389.
126. Yu, T.; Li, J.; Sun, H. C6 ceramide potentiates curcumin-induced cell death and apoptosis in melanoma cell lines in vitro. Cancer Chemother. Pharmacol., 2010, 66(5), 999-1003.
127. Olea-Herrero, N.; Vara, D.; Malagarie-Cazenave, S.; Diaz-Laviada, I. The cannabinoid R+ methanandamide induces IL-6 secretion by prostate cancer PC3 cells. J. Immunotoxicol., 2009, 6(4), 249-256.
128. Park, M.A.; Mitchell, C.; Zhang, G.; Yacoub, A.; Allegood, J.; Haussinger, D.; Reinehr, R.; Larner, A.; Spiegel, S.; Fisher, P.B.; Voelkel-Johnson, C.; Ogretmen, B.; Grant, S.; Dent, P. Vorinostat and sorafenib increase CD95 activation in gastrointestinal tumor cells through a Ca(2+)-de novo ceramide-PP2A-reactive oxygen species-dependent signaling pathway. Cancer Res., 2010, 70(15), 6313-6324.
129. Valsecchi, M.; Aureli, M.; Mauri, L.; Illuzzi, G.; Chigorno, V.; Prinetti, A.; Sonnino, S. Sphingolipidomics of A2780 human ovarian carcinoma cells treated with synthetic retinoids. J. Lipid Res., 2010, 51(7), 1832-1840.
130. Perry, D.K.; Carton, J.; Shah, A.K.; Meredith, F.; Uhlinger, D.J.; Hannun, Y.A. Serine palmitoyltransferase regulates de novo ceramide generation during etoposide-induced apoptosis. J. Biol. Chem., 2000, 275(12), 9078-9084.
131. Kim, D.S.; Kim, S.H.; Song, J.H.; Chang, Y.T.; Hwang, S.Y.; Kim, T.S. Enhancing effects of ceramide derivatives on 1,25-dihydroxyvitamin D(3)-induced differentiation of human HL-60 leukemia cells. Life Sci., 2007, 81(25-26), 1638-1644.
132. Kim, H.J.; Oh, J.E.; Kim, S.W.; Chun, Y.J.; Kim, M.Y. Ceramide induces p38 MAPK-dependent apoptosis and Bax translocation via inhibition of Akt in HL-60 cells. Cancer Lett, 2008, 260(1-2), 88-95.
133. Meng, A.; Luberto, C.; Meier, P.; Bai, A.; Yang, X.; Hannun, Y.A.; Zhou, D. Sphingomyelin synthase as a potential target for D609-induced apoptosis in U937 human monocytic leukemia cells. Exp. Cell Res., 2004, 292(2), 385-392.
134. Separovic, D.; Mann, K.J.; Oleinick, N.L. Association of ceramide accumulation with photodynamic treatment-induced cell death. Photochem. Photobiol., 1998, 68(1), 101-109.
135. Takeda, Y.; Tashima, M.; Takahashi, A.; Uchiyama, T.; Okazaki, T. Ceramide generation in nitric oxide-induced apoptosis. Activation of magnesium-dependent neutral sphingomyelinase via caspase-3. J. Biol. Chem., 1999, 274(15), 10654-10660.
136. Bruno, A.P.; Laurent, G.; Averbeck, D.; Demur, C.; Bonnet, J.; Bettaieb, A.; Levade, T.; Jaffrezou, J.P. Lack of ceramide generation in TF-1 human myeloid leukemic cells resistant to ionizing radiation. Cell Death Differ., 1998, 5(2), 172-182.
137. Senchenkov, A.; Han, T.Y.; Wang, H.; Frankel, A.E.; Kottke, T.J.; Kaufmann, S.H.; Cabot, M.C. Enhanced ceramide generation and induction of apoptosis in human leukemia cells exposed to DT(388)-granulocyte-macrophage colony-stimulating factor (GM-CSF), a truncated diphtheria toxin fused to human GM-CSF. Blood, 2001, 98(6), 1927-1934.
138. Strum, J.C.; Small, G.W.; Pauig, S.B.; Daniel, L.W. 1-beta-D-Arabinofuranosylcytosine stimulates ceramide and diglyceride formation in HL-60 cells. J. Biol. Chem., 1994, 269(22), 15493-15497.
139. Bonhoure, E.; Lauret, A.; Barnes, D.J.; Martin, C.; Malavaud, B.; Kohama, T.; Melo, J.V.; Cuvillier, O. Sphingosine kinase-1 is a downstream regulator of imatinib-induced apoptosis in chronic myeloid leukemia cells. Leukemia, 2008, 22(5), 971-979.
140. Antoon, J.W.; Liu, J.; Ponnapakkam, A.P.; Gestaut, M.M.; Foroozesh, M.; Beckman, B.S. Novel D: -erythro N-octanoyl sphingosine analogs as chemo-and endocrine-resistant breast cancer therapeutics. Cancer Chemother. Pharmacol., 2010, 65(6), 1191-1195.
141. van Vlerken, L.E.; Duan, Z.; Little, S.R.; Seiden, M.V.; Amiji, M.M. Augmentation of therapeutic efficacy in drug-resistant tumor models using ceramide coadministration in temporal-controlled polymer-blend nanoparticle delivery systems. AAPS J., 2010, 12(2), 171-180.
142. Qin, J.D.; Weiss, L.; Slavin, S.; Gatt, S.; Dagan, A. Synthetic, non-natural analogs of ceramide elevate cellular ceramide, inducing apoptotic death to prostate cancer cells and eradicating tumors in mice. Cancer Invest., 2010, 28(5), 535-543.
143. Kiuchi, M.; Adachi, K.; Kohara, T.; Teshima, K.; Masubuchi, Y.; Mishina, T.; Fujita, T. Synthesis and biological evaluation of 2,2-disubstituted 2-aminoethanols: analogues of FTY720. Bioorg. Med. Chem. Lett., 1998, 8(1), 101-106.
144. Liu, Q.; Zhao, X.; Frissora, F.; Ma, Y.; Santhanam, R.; Jarjoura, D.; Lehman, A.; Perrotti, D.; Chen, C.S.; Dalton, J.T.; Muthusamy, N.; Byrd, J.C. FTY720 demonstrates promising preclinical activity for chronic lymphocytic leukemia and lymphoblastic leukemia/ lymphoma. Blood, 2008, 111(1), 275-284.
145. Neviani, P.; Santhanam, R.; Oaks, J.J.; Eiring, A.M.; Notari, M.; Blaser, B.W.; Liu, S.; Trotta, R.; Muthusamy, N.; Gambacorti-Passerini, C.; Druker, B.J.; Cortes, J.; Marcucci, G.; Chen, C.S.; Verrills, N.M.; Roy, D.C.; Caligiuri, M.A.; Bloomfield, C.D.; Byrd, J.C.; Perrotti, D. FTY720, a new alternative for treating blast crisis chronic myelogenous leukemia and Philadelphia chromosome-positive acute lymphocytic leukemia. J. Clin. Invest., 2007, 117(9), 2408-2421.
146. Roberts, K.G.; Smith, A.M.; McDougall, F.; Carpenter, H.; Horan, M.; Neviani, P.; Powell, J.A.; Thomas, D.; Guthridge, M.A.; Perrotti, D.; Sim, A.T.; Ashman, L.K.; Verrills, N.M. Essential requirement for PP2A inhibition by the oncogenic receptor c-KIT suggests PP2A reactivation as a strategy to treat c-KIT+ cancers. Cancer Res., 2010, 70(13), 5438-5447.
147. Perrotti, D.; Neviani, P. Protein phosphatase 2A (PP2A), a drugable tumor suppressor in Ph1(+) leukemias. Cancer Metastasis Rev., 2008, 27(2), 159-168.
148. Li, D.; Zhang, Y.; Hu, X.; Cao, W.; Huang, W. Role of extracelluar regulated protein kinases in FTY720-induced apoptosis of leukemia cell lines HL-60 and U937. J. Huazhong Univ. Sci. Technol. Med. Sci., 2004, 24(1), 45-47.
149. Paugh, S.W.; Payne, S.G.; Barbour, S.E.; Milstien, S.; Spiegel, S. The immunosuppressant FTY720 is phosphorylated by sphingosine kinase type 2. FEBS Lett., 2003, 554(1-2), 189-193.
150. Billich, A.; Bornancin, F.; Devay, P.; Mechtcheriakova, D.; Urtz, N.; Baumruker, T. Phosphorylation of the immunomodulatory drug FTY720 by sphingosine kinases. J. Biol. Chem., 2003, 278(48), 47408-47415.
151. Davis, M.D.; Clemens, J.J.; Macdonald, T.L.; Lynch, K.R. Sphingosine 1-phosphate analogs as receptor antagonists. J. Biol. Chem., 2005, 280(11), 9833-9841.
152. Sanna, M.G.; Wang, S.K.; Gonzalez-Cabrera, P.J.; Don, A.; Marsolais, D.; Matheu, M.P.; Wei, S.H.; Parker, I.; Jo, E.; Cheng, W.C.; Cahalan, M.D.; Wong, C.H.; Rosen, H. Enhancement of capillary leakage and restoration of lymphocyte egress by a chiral S1P1 antagonist in vivo. Nat. Chem. Biol., 2006, 2(8), 434-441.
153. Liu, X.; Cheng, J.C.; Turner, L.S.; Elojeimy, S.; Beckham, T.H.; Bielawska, A.; Keane, T.E.; Hannun, Y.A.; Norris, J.S. Acid ceramidase upregulation in prostate cancer: role in tumor development and implications for therapy. Expert Opin. Ther. Targets, 2009, 13(12), 1449-1458.
154. Gustafsson, K.; Sander, B.; Bielawski, J.; Hannun, Y.A.; Flygare, J. Potentiation of cannabinoid-induced cytotoxicity in mantle cell lymphoma through modulation of ceramide metabolism. Mol. Cancer Res., 2009, 7(7), 1086-1098.
155. Zeng, L.; Biernacka, K.M.; Holly, J.M.; Jarrett, C.; Morrison, A.A.; Morgan, A.; Winters, Z.E.; Foulstone, E.J.; Shield, J.P.; Perks, C.M. Hyperglycaemia confers resistance to chemotherapy on breast cancer cells: the role of fatty acid synthase. Endocr. Relat. Cancer, 2010, 17(2), 539-551.
156. Guillermet-Guibert, J.; Davenne, L.; Pchejetski, D.; Saint-Laurent, N.; Brizuela, L.; Guilbeau-Frugier, C.; Delisle, M.B.; Cuvillier, O.; Susini, C.; Bousquet, C. Targeting the sphingolipid metabolism to defeat pancreatic cancer cell resistance to the chemotherapeutic gemcitabine drug. Mol. Cancer Ther., 2009, 8(4), 809-820.
157. Saddoughi, S.A.; Song, P.; Ogretmen, B. Roles of bioactive sphingolipids in cancer biology and therapeutics. Subcell Biochem., 2008, 49413-440.
158. Chapman, J.V.; Gouaze-Andersson, V.; Messner, M.C.; Flowers, M.; Karimi, R.; Kester, M.; Barth, B.M.; Liu, X.; Liu, Y.Y.; Giuliano, A.E.; Cabot, M.C. Metabolism of short-chain ceramide by human cancer cells--implications for therapeutic approaches. Biochem. Pharmacol., 2010, 80(3), 308-315.
159. Cuvillier, O.; Ader, I.; Bouquerel, P.; Brizuela, L.; Malavaud, B.; Mazerolles, C.; Rischmann, P. Activation of sphingosine kinase-1 in cancer: implications for therapeutic targeting. Curr. Mol. Pharmacol., 2010, 3(2), 53-65.
160. Veldman, R.J.; Koning, G.A.; van Hell, A.; Zerp, S.; Vink, S.R.; Storm, G.; Verheij, M.; van Blitterswijk, W.J. Coformulated N-octanoyl-glucosylceramide improves cellular delivery and cytotoxicity of liposomal doxorubicin. J. Pharmacol. Exp. Ther., 2005, 315(2), 704-710.
161. Shabbits, J.A.; Mayer, L.D. High ceramide content liposomes with in vivo antitumor activity. Anticancer Res., 2003, 23(5A), 3663-3669.
162. van Lummel, M.; van Blitterswijk, W.J.; Vink, S.R.; Veldman, R.J.; van der Valk, M.A.; Schipper, D.; Dicheva, B.M.; Eggermont, A.M.; Ten Hagen, T.L.; Verheij, M.; Koning, G.A. Enriching lipid nanovesicles with short-chain glucosylceramide improves doxorubicin delivery and efficacy in solid tumors. FASEB J., 2010.
163. Stover, T.C.; Sharma, A.; Robertson, G.P.; Kester, M. Systemic delivery of liposomal short-chain ceramide limits solid tumor growth in murine models of breast adenocarcinoma. Clin. Cancer Res., 2005, 11(9), 3465-3474.
164. Teitell, M.A.; Mikkola, H.K. Transcriptional activators, repressors, and epigenetic modifiers controlling hematopoietic stem cell development. Pediatr. Res., 2006, 59 (4 Pt 2), 33R-39R.
165. Pieters, R. Infant acute lymphoblastic leukemia: Lessons learned and future directions. Curr Hematol. Malig. Rep., 2009, 4(3), 167-174.
166. Pieters, R.; Carroll, W.L. Biology and treatment of acute lymphoblastic leukemia. Hematol Oncol Clin. North Am., 2010, 24(1), 1-18.
167. Mandal, C.; Tringali, C.; Mondal, S.; Anastasia, L.; Chandra, S.; Venerando, B. Down regulation of membrane-bound Neu3 constitutes a new potential marker for childhood acute lymphoblastic leukemia and induces apoptosis suppression of neoplastic cells. Int. J. Cancer, 2010, 126(2), 337-349.
168. Merritt, W.D.; Der-Minassian, V.; Reaman, G.H. Increased GD3 ganglioside in plasma of children with T-cell acute lymphoblastic leukemia. Leukemia, 1994, 8(5), 816-822.
169. Mukherjee, K.; Chava, A.K.; Mandal, C.; Dey, S.N.; Kniep, B.; Chandra, S. O-acetylation of GD3 prevents its apoptotic effect and promotes survival of lymphoblasts in childhood acute lymphoblastic leukaemia. J. Cell Biochem., 2008, 105(3), 724-734.
170. O'Donnell, P.H.; Guo, W.X.; Reynolds, C.P.; Maurer, B.J. N-(4-hydroxyphenyl)retinamide increases ceramide and is cytotoxic to acute lymphoblastic leukemia cell lines, but not to non-malignant lymphocytes. Leukemia, 2002, 16(5), 902-910.
171. Reaman, G.H.; Taylor, B.J.; Merritt, W.D. Anti-GD3 monoclonal antibody analysis of childhood T-cell acute lymphoblastic leukemia: detection of a target antigen for antibody-mediated cytolysis. Cancer Res., 1990, 50(1), 202-205.
172. Fais, F.; Tenca, C.; Cimino, G.; Coletti, V.; Zanardi, S.; Bagnara, D.; Saverino, D.; Zarcone, D.; De Rossi, G.; Ciccone, E.; Grossi, C.E. CD1d expression on B-precursor acute lymphoblastic leukemia subsets with poor prognosis. Leukemia, 2005, 19(4), 551-556.
173. Kunii, N.; Horiguchi, S.; Motohashi, S.; Yamamoto, H.; Ueno, N.; Yamamoto, S.; Sakurai, D.; Taniguchi, M.; Nakayama, T.; Okamoto, Y. Combination therapy of in vitro-expanded natural killer T cells and alpha-galactosylceramide-pulsed antigen-presenting cells in patients with recurrent head and neck carcinoma. Cancer Sci., 2009, 100(6), 1092-1098.
174. Song, W.; van der Vliet, H.J.; Tai, Y.T.; Prabhala, R.; Wang, R.; Podar, K.; Catley, L.; Shammas, M.A.; Anderson, K.C.; Balk, S.P.; Exley, M.A.; Munshi, N.C. Generation of antitumor invariant natural killer T cell lines in multiple myeloma and promotion of their functions via lenalidomide: a strategy for immunotherapy. Clin. Cancer Res., 2008, 14(21), 6955-6962.
175. Stirnemann, K.; Romero, J.F.; Baldi, L.; Robert, B.; Cesson, V.; Besra, G.S.; Zauderer, M.; Wurm, F.; Corradin, G.; Mach, J.P.; Macdonald, H.R.; Donda, A. Sustained activation and tumor targeting of NKT cells using a CD1d-anti-HER2-scFv fusion protein induce antitumor effects in mice. J. Clin. Invest., 2008, 118(3), 994-1005.
176. Banchet-Cadeddu, A.; Henon, E.; Dauchez, M.; Renault, J.H.; Monneaux, F.; Haudrechy, A. The stimulating adventure of KRN 7000. Org. Biomol. Chem., 2011.
177. Shiozaki, M.; Tashiro, T.; Koshino, H.; Nakagawa, R.; Inoue, S.; Shigeura, T.; Watarai, H.; Taniguchi, M.; Mori, K. Synthesis and biological activity of ester and ether analogues of alpha-galactosylceramide (KRN7000). Carbohydr. Res., 2010, 345(12), 1663-1684.
178. Veerapen, N.; Reddington, F.; Salio, M.; Cerundolo, V.; Besra, G.S. Synthesis of truncated analogues of the iNKT cell agonist, alpha-galactosyl ceramide (KRN7000), and their biological evaluation. Bioorg. Med. Chem., 2011, 19(1), 221-228.
179. Michieletti, M.; Bracci, A.; Compostella, F.; De Libero, G.; Mori, L.; Fallarini, S.; Lombardi, G.; Panza, L. Synthesis of alpha-galactosyl ceramide (KRN7000) and analogues thereof via a common precursor and their preliminary biological assessment. J. Org. Chem., 2008, 73(22), 9192-9195.
180. Hayakawa, Y.; Rovero, S.; Forni, G.; Smyth, M.J. Alpha-galactosylceramide (KRN7000) suppression of chemical-and oncogene-dependent carcinogenesis. Proc. Natl. Acad. Sci. USA, 2003, 100(16), 9464-9469.
181. Schneiders, F.L.; Scheper, R.J.; von Blomberg, B.M.; Woltman, A.M.; Janssen, H.L.; van den Eertwegh, A.J.; Verheul, H.M.; de Gruijl, T.D.; van der Vliet, H.J. Clinical experience with alpha-galactosylceramide (KRN7000) in patients with advanced cancer and chronic hepatitis B/C infection. Clin. Immunol., 2010.
182. Motohashi, S.; Nagato, K.; Kunii, N.; Yamamoto, H.; Yamasaki, K.; Okita, K.; Hanaoka, H.; Shimizu, N.; Suzuki, M.; Yoshino, I.; Taniguchi, M.; Fujisawa, T.; Nakayama, T. A phase I-II study of alpha-galactosylceramide-pulsed IL-2/GM-CSF-cultured peripheral blood mononuclear cells in patients with advanced and recurrent non-small cell lung cancer. J. Immunol., 2009, 182(4), 2492-2501.
183. Motohashi, S.; Ishikawa, A.; Ishikawa, E.; Otsuji, M.; Iizasa, T.; Hanaoka, H.; Shimizu, N.; Horiguchi, S.; Okamoto, Y.; Fujii, S.; Taniguchi, M.; Fujisawa, T.; Nakayama, T. A phase I study of in vitro expanded natural killer T cells in patients with advanced and recurrent non-small cell lung cancer. Clin. Cancer Res., 2006, 12(20 Pt 1), 6079-6086.
184. Ishikawa, A.; Motohashi, S.; Ishikawa, E.; Fuchida, H.; Higashino, K.; Otsuji, M.; Iizasa, T.; Nakayama, T.; Taniguchi, M.; Fujisawa, T. A phase I study of alpha-galactosylceramide (KRN7000)-pulsed dendritic cells in patients with advanced and recurrent non-small cell lung cancer. Clin. Cancer Res., 2005, 11(5), 1910-1917.
185. Giaccone, G.; Punt, C.J.; Ando, Y.; Ruijter, R.; Nishi, N.; Peters, M.; von Blomberg, B.M.; Scheper, R.J.; van der Vliet, H.J.; van den Eertwegh, A.J.; Roelvink, M.; Beijnen, J.; Zwierzina, H.; Pinedo, H.M. A phase I study of the natural killer T-cell ligand alpha-galactosylceramide (KRN7000) in patients with solid tumors. Clin. Cancer Res., 2002, 8(12), 3702-3709.
186. Le Beau, M.M.; Albain, K.S.; Larson, R.A.; Vardiman, J.W.; Davis, E.M.; Blough, R.R.; Golomb, H.M.; Rowley, J.D. Clinical and cytogenetic correlations in 63 patients with therapy-related myelodysplastic syndromes and acute nonlymphocytic leukemia: further evidence for characteristic abnormalities of chromosomes no. 5 and 7. J. Clin. Oncol., 1986, 4(3), 325-345.
187. Cakir, Z.; Saydam, G.; Sahin, F.; Baran, Y. The roles of bioactive sphingolipids in resveratrol-induced apoptosis in HL60: acute myeloid leukemia cells. J. Cancer Res. Clin. Oncol., 2010.
188. Dbaibo, G.S.; Kfoury, Y.; Darwiche, N.; Panjarian, S.; Kozhaya, L.; Nasr, R.; Abdallah, M.; Hermine, O.; El-Sabban, M.; de The, H.; Bazarbachi, A. Arsenic trioxide induces accumulation of cytotoxic levels of ceramide in acute promyelocytic leukemia and adult T-cell leukemia/lymphoma cells through de novo ceramide synthesis and inhibition of glucosylceramide synthase activity. Haematologica, 2007, 92(6), 753-762.
189. Kondo, T.; Matsuda, T.; Kitano, T.; Takahashi, A.; Tashima, M.; Ishikura, H.; Umehara, H.; Domae, N.; Uchiyama, T.; Okazaki, T. Role of c-jun expression increased by heat shock-and ceramide-activated caspase-3 in HL-60 cell apoptosis. Possible involvement of ceramide in heat shock-induced apoptosis. J. Biol. Chem., 2000, 275(11), 7668-7676.
190. Nieda, M.; Nicol, A.; Koezuka, Y.; Kikuchi, A.; Lapteva, N.; Tanaka, Y.; Tokunaga, K.; Suzuki, K.; Kayagaki, N.; Yagita, H.; Hirai, H.; Juji, T. TRAIL expression by activated human CD4(+)V alpha 24NKT cells induces in vitro and in vivo apoptosis of human acute myeloid leukemia cells. Blood, 2001, 97(7), 2067-2074.
191. Murate, T.; Suzuki, M.; Hattori, M.; Takagi, A.; Kojima, T.; Tanizawa, T.; Asano, H.; Hotta, T.; Saito, H.; Yoshida, S.; Tamiya-Koizumi, K. Up-regulation of acid sphingomyelinase during retinoic acid-induced myeloid differentiation of NB4, a human acute promyelocytic leukemia cell line. J. Biol. Chem., 2002, 277(12), 9936-9943.
192. Nojiri, H.; Kitagawa, S.; Nakamura, M.; Kirito, K.; Enomoto, Y.; Saito, M. Neolacto-series gangliosides induce granulocytic differentiation of human promyelocytic leukemia cell line HL-60. J. Biol. Chem., 1988, 263(16), 7443-7446.
193. Arai, K.; Taki, T.; Kondo, A.; Matsumoto, M. Ganglioside GM3 as a modulator of differentiation of mouse myeloid leukemia cells (M1-T22). Cell Struct. Funct., 1988, 13(2), 161-169.
194. Turzanski, J.; Grundy, M.; Shang, S.; Russell, N.; Pallis, M. P-glycoprotein is implicated in the inhibition of ceramide-induced apoptosis in TF-1 acute myeloid leukemia cells by modulation of the glucosylceramide synthase pathway. Exp. Hematol., 2005, 33(1), 62-72.
195. Pallis, M.; Russell, N. P-glycoprotein plays a drug-efflux-independent role in augmenting cell survival in acute myeloblastic leukemia and is associated with modulation of a sphingomyelin-ceramide apoptotic pathway. Blood, 2000, 95(9), 2897-2904.
196. Bonhoure, E.; Pchejetski, D.; Aouali, N.; Morjani, H.; Levade, T.; Kohama, T.; Cuvillier, O. Overcoming MDR-associated chemoresistance in HL-60 acute myeloid leukemia cells by targeting sphingosine kinase-1. Leukemia, 2006, 20(1), 95-102.
197. Le Scolan, E.; Pchejetski, D.; Banno, Y.; Denis, N.; Mayeux, P.; Vainchenker, W.; Levade, T.; Moreau-Gachelin, F. Overexpression of sphingosine kinase 1 is an oncogenic event in erythroleukemic progression. Blood, 2005, 106(5), 1808-1816.
198. Reed, J.C. Molecular biology of chronic lymphocytic leukemia. Semin. Oncol., 1998, 25(1), 11-18.
199. Liu, X.; Ryland, L.; Yang, J.; Liao, A.; Aliaga, C.; Watts, R.; Tan, S.F.; Kaiser, J.; Shanmugavelandy, S.S.; Rogers, A.; Loughran, K.; Petersen, B.; Yuen, J.; Meng, F.; Baab, K.T.; Jarbadan, N.R.; Broeg, K.; Zhang, R.; Liao, J.; Sayers, T.J.; Kester, M.; Loughran, T.P. Targeting of survivin by nanoliposomal ceramide induces complete remission in a rat model of NK-LGL leukemia. Blood, 2010, 116(20), 4192-4201.
200. O'Boyle, K.P.; Freeman, K.; Kalisiak, A.; Agregado, A.; Scheinberg, D.A. Patterns of ganglioside expression in B cell neoplasms. Leuk. Lymphoma, 1996, 21(3-4), 255-266.
201. Pick, J.; Anh-Tuan, N.; Mod, A.; Hollan, S. Ganglioside composition in common acute lymphoblastic leukaemia. Haematologia (Budap), 1986, 19(1), 33-39.
202. Mone, A.P.; Cheney, C.; Banks, A.L.; Tridandapani, S.; Mehter, N.; Guster, S.; Lin, T.; Eisenbeis, C.F.; Young, D.C.; Byrd, J.C. Alemtuzumab induces caspase-independent cell death in human chronic lymphocytic leukemia cells through a lipid raft-dependent mechanism. Leukemia, 2006, 20(2), 272-279.
203. Fais, F.; Morabito, F.; Stelitano, C.; Callea, V.; Zanardi, S.; Scudeletti, M.; Varese, P.; Ciccone, E.; Grossi, C.E. CD1d is expressed on B-chronic lymphocytic leukemia cells and mediates alpha-galactosylceramide presentation to natural killer T lymphocytes. Int. J. Cancer, 2004, 109(3), 402-411.
204. Tough, I.M.; Court Brown, W.M.; Baikie, A.G.; Buckton, K.E.; Harnden, D.G.; Jacobs, P.A.; King, M.J.; Mc, B.J. Cytogenetic studies in chronic myeloid leukaemia and acute leukaemia associated with monogolism. Lancet, 1961, 1(7174), 411-417.
205. Stegmeier, F.; Warmuth, M.; Sellers, W.R.; Dorsch, M. Targeted cancer therapies in the twenty-first century: lessons from imatinib. Clin Pharmacol Ther, 2010, 87(5), 543-552.
206. Gora-Tybor, J.; Robak, T. Targeted drugs in chronic myeloid leukemia. Curr. Med. Chem., 2008, 15(29), 3036-3051.
207. Baran, Y.; Salas, A.; Senkal, C.E.; Gunduz, U.; Bielawski, J.; Obeid, L.M.; Ogretmen, B. Alterations of ceramide/sphingosine 1-phosphate rheostat involved in the regulation of resistance to imatinib-induced apoptosis in K562 human chronic myeloid leukemia cells. J. Biol. Chem., 2007, 282(15), 10922-10934.
208. Nica, A.F.; Tsao, C.C.; Watt, J.C.; Jiffar, T.; Kurinna, S.; Jurasz, P.; Konopleva, M.; Andreeff, M.; Radomski, M.W.; Ruvolo, P.P. Ceramide promotes apoptosis in chronic myelogenous leukemia-derived K562 cells by a mechanism involving caspase-8 and JNK. Cell Cycle, 2008, 7(21), 3362-3370.
209. McGahon, A.J.; Nishioka, W.K.; Martin, S.J.; Mahboubi, A.; Cotter, T.G.; Green, D.R. Regulation of the Fas apoptotic cell death pathway by Abl. J. Biol. Chem., 1995, 270(38), 22625-22631.
210. Tringali, C.; Lupo, B.; Cirillo, F.; Papini, N.; Anastasia, L.; Lamorte, G.; Colombi, P.; Bresciani, R.; Monti, E.; Tettamanti, G.; Venerando, B. Silencing of membrane-associated sialidase Neu3 diminishes apoptosis resistance and triggers megakaryocytic differentiation of chronic myeloid leukemic cells K562 through the increase of ganglioside GM3. Cell Death Differ., 2009, 16(1), 164-174.
211. Nakamura, M.; Kirito, K.; Yamanoi, J.; Wainai, T.; Nojiri, H.; Saito, M. Ganglioside GM3 can induce megakaryocytoid differentiation of human leukemia cell line K562 cells. Cancer Res., 1991, 51(7), 1940-1945.
212. Tringali, C.; Lupo, B.; Anastasia, L.; Papini, N.; Monti, E.; Bresciani, R.; Tettamanti, G.; Venerando, B. Expression of sialidase Neu2 in leukemic K562 cells induces apoptosis by impairing Bcr-Abl/Src kinases signaling. J. Biol. Chem., 2007, 282(19), 14364-14372.
213. Cebo, C.; Da Rocha, S.; Wittnebel, S.; Turhan, A.G.; Abdelali, J.; Caillat-Zucman, S.; Bourhis, J.H.; Chouaib, S.; Caignard, A. The decreased susceptibility of Bcr/Abl targets to NK cell-mediated lysis in response to imatinib mesylate involves modulation of NKG2D ligands, GM1 expression, and synapse formation. J. Immunol., 2006, 176(2), 864-872.
214. Macher, B.A.; Buehler, J.; Scudder, P.; Knapp, W.; Feizi, T. A novel carbohydrate, differentiation antigen on fucogangliosides of human myeloid cells recognized by monoclonal antibody VIM-2. J Biol Chem., 1988, 263(21), 10186-10191.
215. Fukuda, M.N.; Dell, A.; Tiller, P.R.; Varki, A.; Klock, J.C.; Fukuda, M. Structure of a novel sialylated fucosyl lacto-N-norhexaosylceramide isolated from chronic myelogenous leukemia cells. J. Biol. Chem., 1986, 261(5), 2376-2383.
216. Mondal, S.; Mandal, C.; Sangwan, R.; Chandra, S. Withanolide D induces apoptosis in leukemia by targeting the activation of neutral sphingomyelinase-ceramide cascade mediated by synergistic activation of c-Jun N-terminal kinase and p38 mitogen-activated protein kinase. Mol. Cancer, 2010, 39-92.
217. Modrak, D.E.; Leon, E.; Goldenberg, D.M.; Gold, D.V. Ceramide regulates gemcitabine-induced senescence and apoptosis in human pancreatic cancer cell lines. Mol. Cancer Res., 2009, 7(6), 890-896.
218. Lin, C.F.; Chen, C.L.; Lin, Y.S. Ceramide in apoptotic signaling and anticancer therapy. Curr. Med. Chem., 2006, 13(14), 1609-1616.
219. Dumitru, C.A.; Sandalcioglu, I.E.; Wagner, M.; Weller, M.; Gulbins, E. Lysosomal ceramide mediates gemcitabine-induced death of glioma cells. J. Mol. Med., 2009, 87(11), 1123-1132.
220. Min, J.; Mesika, A.; Sivaguru, M.; Van Veldhoven, P.P.; Alexander, H.; Futerman, A.H.; Alexander, S. (Dihydro)ceramide synthase 1 regulated sensitivity to cisplatin is associated with the activation of p38 mitogen-activated protein kinase and is abrogated by sphingosine kinase 1. Mol. Cancer Res., 2007, 5(8), 801-812.
221. Litvak, D.A.; Bilchik, A.J.; Cabot, M.C. Modulators of ceramide metabolism sensitize colorectal cancer cells to chemotherapy: a novel treatment strategy. J. Gastrointest. Surg., 2003, 7(1), 140-148; discussion 148.
222. Gouaze-Andersson, V.; Flowers, M.; Karimi, R.; Fabrias, G.; Delgado, A.; Casas, J.; Cabot, M.C. Inhibition of acid ceramidase by a 2-substituted aminoethanol amide synergistically sensitizes prostate cancer cells to N-(4-hydroxyphenyl) retinamide. Prostate, 2010.
223. Ji, C.; Yang, B.; Yang, Y.L.; He, S.H.; Miao, D.S.; He, L.; Bi, Z.G. Exogenous cell-permeable C6 ceramide sensitizes multiple cancer cell lines to Doxorubicin-induced apoptosis by promoting AMPK activation and mTORC1 inhibition. Oncogene, 2010, 29(50), 6557-6568.
224. Senkal, C.E.; Ponnusamy, S.; Rossi, M.J.; Sundararaj, K.; Szulc, Z.; Bielawski, J.; Bielawska, A.; Meyer, M.; Cobanoglu, B.; Koybasi, S.; Sinha, D.; Day, T.A.; Obeid, L.M.; Hannun, Y.A.; Ogretmen, B. Potent antitumor activity of a novel cationic pyridinium-ceramide alone or in combination with gemcitabine against human head and neck squamous cell carcinomas in vitro and in vivo. J. Pharmacol. Exp. Ther., 2006, 317(3), 1188-1199.
225. Ogretmen, B.; Hannun, Y.A. Biologically active sphingolipids in cancer pathogenesis and treatment. Nat. Rev. Cancer, 2004, 4(8), 604-616.
226. Oskouian, B.; Saba, J.D. Cancer treatment strategies targeting sphingolipid metabolism. Adv. Exp. Med. Biol., 2010, 688, 185-205.